Immunome Director Isaac Barchas Sells $2.6 Million in Stock

Immunome director Isaac Barchas sold 98,712 shares of company stock between August 10 and August 12, 2026, for approximately $2.6 million. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan and disclosed in filings with the Securities and Exchange Commission. These sales followed a series of divestments Barchas made throughout June and July.

The stock activity coincided with Immunome reporting its second-quarter 2026 financial results. The company posted a quarterly loss of $0.65 per share, which was wider than the consensus estimate of a $0.51 loss.

Despite the earnings miss, Immunome stock rose 6.6% to $27.99 on August 12. This upward movement was supported by Truist Financial, which maintained a "Buy" rating and increased its price target for the company to $38.